

PATENT
030639.0034.CPA1In the Claims

Please amend claims 38 and 40-47 as follows.

E2 1 ~~38~~. (Amended) A method of treating insulin-requiring diabetes mellitus in a mammal comprising administering to said mammal an effective amount of an insulin and an effective amount of a glucagon-like peptide 1 (7-36) amide analogue, wherein said glucagon-like peptide 1 (7-36) amide analogue is administered subcutaneously.

E5 3 ~~40~~. (Amended) A method according to claim ~~39~~² wherein said insulin and said glucagon-like peptide 1 (7-36) amide analogue are administered to the human at a selected time prior to ingestion of a meal.

E6 4 ~~41~~. (Amended) A method according to any of claims ~~38-40~~¹⁻³ wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-36).

E3 F 5 ~~42~~. (Amended) A method according to any of claims ~~38-41~~¹⁻³ wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-37).

E7 6 ~~43~~. (Amended) A method of treating insulin-requiring diabetes mellitus in a mammal comprising administering an effective amount of a glucagon-like peptide 1 (7-36) amide analogue, wherein said glucagon-like peptide 1 (7-36) amide analogue is administered subcutaneously.

E8 7 ~~44~~. (Amended) A method according to claim ~~43~~⁶ wherein said mammal is a human.

E9 8 ~~45~~. (Amended) A method according to claim ~~44~~⁷ wherein said glucagon-like peptide 1 (7-36) amide analogue is administered to the human at a selected time prior to ingestion of a meal.

E10 9 ~~46~~. (Amended) A method according to any of claims ~~43-45~~⁶⁻⁸ wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-37).

PATENT
030639.0034.CPA1

11 10 47. (Amended) A method according to any of claims ~~43-45~~⁶⁻⁸ wherein said glucagon-like peptide 1 (7-36) amide analogue is glucagon-like peptide 1 (7-36).

Please add the following new claims 48-52.

11 48. (New) A method of treating insulin-requiring diabetes in a mammal comprising administering subcutaneously to the mammal an effective amount of a peptide selected from the group consisting of

- (a) glucagon-like peptide 1 (7-37);
(b) glucagon-like peptide 1 (7-36) amide; and
(c) an effective fragment or analogue of (a) or (b).

12 49. (New) The method of claim ~~48~~¹¹ further comprising administering an insulin.

13 50. (New) A method of treating insulin-requiring diabetes in a mammal comprising administering subcutaneously to the mammal an effective amount of a glucagon-like peptide 1-related peptide.

14 51. (New) The method of claim ~~50~~¹³ further comprising administering an insulin.

15 52. (New) The method according to any of claims ~~38, 43, 48~~^{1 6 11 13} and ~~50~~ wherein the insulin-requiring diabetes is Type I diabetes.--

REMARKS

Claims 38-52 are pending in the instant application. Claims 48-52 have been added, and find full support in the specification, as do the amendments to the existing claims. For example, amendments to all claims are supported on page 2, lines 1-12.